NASDAQ
01.11.24
20:26 Uhr
0,510 US-Dollar
+0,020
+4,10 %
+4,10 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.10. | Eyenovia reveals Optejet dispenser benefits in study | 1 | Investing.com | ||
| 16.10. | Eyenovia, Inc.: Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo | 2 | GlobeNewswire (USA) | ||
| 01.10. | Eyenovia (EYEN) files for $100M mixed shelf offering | 6 | Seeking Alpha | ||
| 01.10. | Eyenovia, Inc.: Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device | 5 | GlobeNewswire (USA) | ||
| 30.09. | EYENOVIA, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 27.09. | Eyenovia stock slides on pricing capital raise of about $4 million via securities offering | 2 | Seeking Alpha | ||
| 27.09. | Eyenovia sichert sich 4 Millionen US-Dollar durch direkte Aktienplatzierung | 1 | Investing.com Deutsch | ||
| 27.09. | Eyenovia secures $4 million in registered direct offering | 1 | Investing.com | ||
| 27.09. | Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering | 4 | GlobeNewswire (USA) | ||
| 26.09. | Eyenovia announces commercial availability of clobetasol, shares rise | 3 | Seeking Alpha | ||
| 26.09. | Eyenovia, Inc.: Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery | 3 | GlobeNewswire (USA) | ||
| 20.09. | Eyenovia faces Nasdaq delisting over share price dip | 2 | Investing.com | ||
| 20.09. | Eyenovia droht Delisting von der Nasdaq wegen Kursrückgang | 9 | Investing.com Deutsch | ||
| 20.09. | EYENOVIA, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.09. | Eyenovia, Inc.: Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S. | 1 | GlobeNewswire (USA) | ||
| 03.09. | Eyenovia appoints Andrew Jones CFO | 1 | Seeking Alpha | ||
| 03.09. | Eyenovia appoints Andrew Jones as new CFO | 1 | Investing.com | ||
| 03.09. | EYENOVIA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.09. | Eyenovia, Inc.: Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer | 138 | GlobeNewswire (Europe) | NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia... ► Artikel lesen | |
| 29.08. | Eyenovia CEO Michael Rowe buys $14k of company stock | 1 | Investing.com |
Seite:
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 10,200 | -2,86 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Global Angioedema Forum | Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts... ► Artikel lesen | |
| ROCKET LAB USA | 10,440 | -0,76 % | Could Rocket Lab Be a Millionaire-Maker Stock in the Trillion-Dollar Space Industry? | ||
| BOIRON | 32,450 | +1,25 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| HARROW | 45,500 | +1,97 % | Harrow Unusual Options Activity For October 28 | ||
| MEDICINOVA | 1,600 | 0,00 % | MediciNova, Inc.: MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) | LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 1,520 | -69,66 % | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,480 | -0,18 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm | Applauds first FDA approval of non-injection-based epinephrine deviceReiterates expected timing for filing of New Drug Application (NDA) for Anaphylm (epinephrine) Sublingual Film to the FDA in the... ► Artikel lesen | |
| SHINECO | 0,134 | +1,36 % | Shineco, Inc.: Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement | BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 0,995 | -11,16 % | Reviva Pharmaceuticals: Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia | - Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia - - Additional vocal... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 1,100 | -1,79 % | Cumberland Pharma stock hits 52-week low at $1.18 | ||
| CYANOTECH | 0,260 | 0,00 % | Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025 | KAILUA KONA, Hawaii--(BUSINESS WIRE)--Cyanotech Corporation (OTCQB: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results... ► Artikel lesen | |
| LYRA THERAPEUTICS | 0,262 | -4,62 % | Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis | -- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company... ► Artikel lesen | |
| OMNIAB | 4,175 | +2,08 % | OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates.
"Second... ► Artikel lesen | |
| ONKURE THERAPEUTICS | 16,075 | -8,14 % | OnKure Therapeutics, Inc.: OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium | ||
| BAYER | 25,100 | +1,23 % | Bayer, BASF und Co: Von diesen DAX-Aktien würde jetzt (fast) jeder Analyst die Finger lassen | Von Bayer über BASF bis zu Brenntag und mehr: Sollten Anleger bei diesen DAX-Titeln eher auf Abstand gehen? Zumindest würden fast alle Analysten, die die Aktien beobachten, derzeit keinen Kauf in Erwägung... ► Artikel lesen |
Das Unternehmen EYENOVIA INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,020 (+4,10 %) liegt der Kurs bei 0,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EYENOVIA INC finden Sie auf Wallstreet Online.
